MAD2L2 and cancer: However, recent progress in basic and clinical cancer research reveals REV7 to be a possible predictive biomarker for the effectiveness of DNA-damaging chemotherapy or PARP inhibitors and for the prognosis of cancer patients; it is also an attractive molecular target for the enhancement of DNA-damaging chemotherapy.